Showing results (241-250 of 289) with videos related to

Sort By:
Pageof 29
Oncotarget|March 31, 2016
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinomaDaniele Santini, Matteo Santoni, Alessandro Conti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 StudyEmmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, et al.
The Journal of Urology|November 30, 2014
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinomaRoberto Iacovelli, Alessio Farcomeni, Cora N Sternberg, et al.
NEJM Evidence|February 6, 2024
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate CancerNoel W Clarke, Andrew J Armstrong, Antoine Thiery-Vuillemin, et al.
European Urology Oncology|June 3, 2025
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter ExperienceGiuseppina Bruno, Maria Iole Natalicchio, Marianna Garofoli, et al.
Oncotarget|May 26, 2016
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort studyElena Verzoni, Ugo De Giorgi, Lisa Derosa, et al.
Plos One|January 4, 2014
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyDaniele Santini, Giuseppe Procopio, Camillo Porta, et al.
The New England Journal of Medicine|September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaRobert J Motzer, Bernard Escudier, David F McDermott, et al.
Tumori|June 8, 2022
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)Caterina Caminiti, Jane Bryce, Silvia Riva, et al.
Clinical Genitourinary Cancer|October 26, 2024
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World StudyAnna Patrikidou, Calogero Saieva, Richard Lee-Ying, et al.
Pageof 29